An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies
Top Cited Papers
Open Access
- 1 January 2017
- journal article
- review article
- Published by Mary Ann Liebert Inc in Cannabis and Cannabinoid Research
- Vol. 2 (1), 139-154
- https://doi.org/10.1089/can.2016.0034
Abstract
Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy and psychotic disorders. Here, the most commonly reported side effects were tiredness, diarrhea, and changes of appetite/weight. In comparison with other drugs, used for the treatment of these medical conditions, CBD has a better side effect profile. This could improve patients' compliance and adherence to treatment. CBD is often used as adjunct therapy. Therefore, more clinical research is warranted on CBD action on hepatic enzymes, drug transporters, and interactions with other drugs and to see if this mainly leads to positive or negative effects, for example, reducing the needed clobazam doses in epilepsy and therefore clobazam's side effects. Conclusion: This review also illustrates that some important toxicological parameters are yet to be studied, for example, if CBD has an effect on hormones. Additionally, more clinical trials with a greater number of participants and longer chronic CBD administration are still lacking.Keywords
This publication has 71 references indexed in Scilit:
- Cannabidiol for the treatment of cannabis withdrawal syndrome: a case reportJournal of Clinical Pharmacy & Therapeutics, 2013
- Non‐THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro‐apoptotic effects and underlying mechanismsBritish Journal of Pharmacology, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen CannabisNeuropsychopharmacology, 2010
- Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal DisturbancesJournal of Neuroscience, 2009
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In VivoJournal of Pharmacology and Experimental Therapeutics, 2009
- Cannabidiol arrests onset of autoimmune diabetes in NOD miceNeuropharmacology, 2008
- Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cellsMolecular Cancer Therapeutics, 2007
- Inhibition of hepatic microsomal cytochrome P450 by cannabidiol in adult male rats.CHEMICAL & PHARMACEUTICAL BULLETIN, 1990